Srinivas Garlapati

Experienced educator, researcher, project manager, and author prepared for this role with a strong background in academic research, curriculum development, and student mentorship. Focus on team collaboration and achieving results ensures adaptability to changing academic environments. Skilled in classroom instruction, scholarly writing, and fostering a positive learning atmosphere. Known for reliability and ability to drive educational success through innovative teaching methods and collaborative projects.

Prepared healthcare professionals to manage value-based and patient-centered healthcare services. Published peer-reviewed research articles in high-impact factor journals with more than 600 citations. Authored and edited a textbook on Healthcare administration and management - A Canadian context, published by Nature Springer. Managed highly impactful research projects impacting global health. Supported and guided healthcare professionals to improve evidence-based implementation of research methods in management and leadership. Managed healthcare management instructors in delivering curriculum to students in healthcare leadership and communication courses.

• Project Management Institute

PMP professional.

Black Belt in Lean Six-Sigma in healthcare.

Certification Interprofessional health education.

Institute of Health Information Quality Improvement

Public Health Program Evaluation

Total Publications = 14; Total citations: 495; H- Index=10)

1. Polewicz M, Gracia A, Srinivas Garlapati, van Kessel J, Strom S, Halperin SA, Hancock RE, Potter AA, Babiuk LA, Gerdts V Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies. (2013). Vaccine 28;31(31):3148-55. (IF=3.143, Citations=59). My contributions: I contributed ~20% to the article by developing the microparticle delivery system and also trained the graduate student Polewicz M. We used the murine and porcine model for testing the protective efficacy of a novel adjuvant-microparticles against pertussis. The work is significant as it demonstrated that encapsulation of antigens in microparticles can overcome maternal antibodies and provide early protection. The work was part of the Doctoral thesis of Monika Polewicz, University of Saskatchewan. The work was funded by the Bill and Melinda Gates Foundation Grand Challenges Program to Lorne Babiuk and Collaborators.

2. Srinivas Garlapati (2012). Do we know the Th1/Th2/Th17 determinants of vaccine response?

Expert Reviews of Vaccines 11(11):1307-10. (IF=4.22, Citations=13). My contributions: The above work was to explore how antigens and adjuvants can determine the types of T-cell immune response. I contributed 100% to the work. Evaluation of: Kamath AT, Mastelic B, Christensen D et al. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. J. Immunol. 188(10), 4828-4837 (2012). The role of delivery systems for codelivery of adjuvant and Ag to the same dendritic cell has gained acceptance. The milieu in which dendritic cells process and present Ag to naive CD4+ T cells determines their polarization into different subsets.

3. Srinivas Garlapati*, Garg R*, Brownlie R, Latimer L, Simko S, Hancock REW, Babiuk LA, Gerdts V, Potter, A and Van Drunen Littel-Van den Hurk, S.(2012). Enhanced immune responses and protection by vaccination with respiratory syncytial viral fusion protein formulated with CpG oligodeoxynucleotide and synthetic innate defence regulator peptide in polyphosphazene microparticles. Vaccine 30(35):5206-14. (IF=4.22, Citations=54). My contributions: I contributed ~80% through developing the antigen-adjuvant formulation and training of technicians and writing and reviewing of the manuscript. This work was supported by grants from the Krembil Foundation, the Canadian Institutes of Health Research (CIHR) and the Bill and Melinda Gates Foundation. The paper was published from the lab or Sylvia A Van Drnen Little-Van den Hurk. The paper looked at using the combination of Triple adjuvants of CpG, Polyphosphazene and Innate defense regulator peptide. The vaccine aimed to develop vaccines against RSV for which no vaccine exists till now.

4. Srinivas Garlapati*, Eng NF*, Kiros TG, Kindrachuk J, Mutwiri GK, Hancock RE, Halperin SA, Potter AA, Babiuk LA, Gerdts V. (2011). Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine2;29(38):6540-8. (IF=4.22, Citations=51). My contributions to this paper was ~80% through vaccine formulation, experimental design, enumeration and statistical analysis of Antibody titres, T-cell responses, and Cytokines in the lungs. The work was done in collaboration with University of British Columbia and Dalhousie University. In this study we demonstrated that when our adjuvant was formulated into microparticles enhanced the T-cell responses and a balanced Th1/Th2 leading to enhanced protection than when formulated in solution.

5. George Mutwiri, Volker Gerdts, Sylvia van Drunen Littel-van den Hurk, Gael Auray, Nelson Eng, Srinivas Garlapati, Lorne A. Babiuk, Andy Potter. (2011). Combination adjuvants: the next generation of adjuvants. Expert Reviews of Vaccines, 10(1):95-107. (IF=4.22, Citations=55). My contributionsto this review was ~10%.

6. Saravanan Thiagirajan, Chockalingam AK, N. Govindasamy, R. Patnaikuni, S. Garlapati, R.R.Golla, D.H. Joyappa and V.V.S. Veluvarthy. (2011). Construction of genome-length cDNA for foot-and-mouth disease virus serotype Asia 1 IND 63/72 vaccine strain. International Journal of Biotechnology and Molecular Biology Research,2(2):39-45 (IF=0.768, Citations=5). My contributions to this work was ~10% and was part of the Doctoral thesis of Saravanan Thiagirajan at the Molecular Virology Lab, Indian Veterinary Research Institute, Bangalore.

7. Srinivas Garlapati*, Nelson F. Eng* Wilson HL, Buchanan R, Mutwiri GK, Babiuk LA, Gerdts V. (2010). PCPP microparticles co-encapsulating ovalbumin and CpG ODN are potent enhancers of antigen specific Th1 immune responses in mice. Vaccine, 28(52):8306-14. (IF=3.143, Citations=30). My contributions to this work was ~80%. My contributions to this paper was ~80% through vaccine formulation, experimental design, enumeration and statistical analysis of Antibody titres, Release kinetics ofAdjuvant and Antigens, mouse whole body scanning studies, lymph node studies, writing and editing of the manucscript. The work demonstrated a proof of concept for co-encapsulation and co-delivery of antigen and adjuvant to Dendritic Cells. The study also elucidated the real time visualization of antigen and adjuvant using mouse whole body scanning. A Th1 shift in immune responses was observed when formulated into microparticles rather than the soluble formulations of the same adjuvant.

8. Nelson F. Eng*, Srinivas Garlapati* Gerdts V, Babiuk LA, Mutwiri GK. (2010). PCEP enhances IgA mucosal immune responses in mice following intranasal immunization with influenza virus antigens. Journal of Immune Based Therapeutics and Vaccines 8(1):4. (Citations=20). My contribution to this work was ~10%. The study was designed by Nelson F. Eng in George Mutwiri’s Lab. The work was funded by Krembil foundation and Bill and Melinda Gates Foundation. The work elucidated that polyphospazene adjuvant can be used to elicit mucosal immune responses

9. Nelson F. Eng, Srinivas Garlapati, Gerdts V, Potter A, Babiuk LA, Mutwiri GK. (2010). The potential of polyphosphazenes for delivery of vaccine antigens and immunotherapeutic agents. Current Drug Delivery 7: 13-20. (IF=1.582, Citations=34). My contribution to the review was ~20%. I contributed to the vaccine delivery systems discussed in the review.

10. Chockalingam AK S. Thiyagarajan, N. Govindasamy, R. Patnaikuni, Srinivas Garlapati, R.R.Golla, D.H. Joyappa, P. Krishnamshetty , V.V.S. Veluvarthy. (2010). Study of a chimeric Foot-and-mouth disease virus DNA vaccine containing structural genes of serotype O in a genome backbone of serotype Asia 1 in guinea pigs.   Acta Virologica 54(3):189-95. (IF=0.793, h-index=31 Citations=3). My contribution to this work is ~10%. Contributed to the team by help in designing the work and reviewing the manuscript. Chimeric viruses role as vaccine candidates was elucidated.

11. Nelson F Eng, Srinivas Garlapati, Ken Lai, Volker Gerdts, Lorne A. Babiuk, George Mutwiri. Open Vaccine Journal 2(10):134-143. (2009). PCPP and PCEP enhance systemic and mucosal immuneresponses in mice with influenza virus antigens. (h-index=9 Citations=3). My contributions to this work was ~30%. I contributed to the design of vaccine formulation, animal experimental design, enumeration and statistical analysis of Antibody titers, T-cell responses.. This work was a proof of concept demonstrating that the polyphospazene adjuvants can elicit systemic and mucosal immune responses in influenza mouse models

12. Srinivas Garlapati, Facci M, Polewicz M, Strom S, Babiuk LA, Mutwiri G, Hancock RE, Elliott MR, Gerdts V. (2009). Strategies to link innate and adaptive immunity when designing vaccine adjuvants. Vet. Immunology Immunopathology 128(1-3):184-91. (IF=1.713, Citations=40). My contributions to this paper was ~80% through microparticle generation, macrophage cell culture, microparticle uptake analysis, fluorescent microscopy to demonstrate particle uptake. The work was presented at part of Veterinary Immunology and immunopathology conference 2008. Manuscript was co-authored along with Marina Facci a graduate student.

13. Ravi Kumar GV, Srinivas Garlapati Ravi Kumar P, Suryanarayana VVS, Sharma A., et al. (2008). Sequencing, characterization and genetic variation of the Bos indicus glucose-6-phosphate dehydrogenase gene. DNA Sequence19(1):37-43. (IF=NA, Citations=2). My contribution to the work was around 30%. I performed the phylogenetic analysis of the Bos indicus Glucose-6-phosphate dehydrogenase gene.

14. Srinivas Garlapati. (2002). Application of Genomics and Bioinformatics in Parasitology.  Journal of Veterinary Parasitology 16(2):95-105.My contribution to the review was 100%.

(*contributed equally)

GenBank Submissions

1. Nagesh, M. Srinivas Garlapati., Vidhya, H., Suryanarayana, V., Hussaini, S. and Rabindra, R.J. (2016) Cloning and Sequencing of TCD Toxin gene of Photorhabdus luminiscens. NCBI Accession number: AH014524

My contributions to the work involved designing of the PCR primers for amplifying the gene fragment, setting up the conditions for PCR amplification, analysis of the DNA sequence, and submission of the sequence to the Genbank.

2. Nagesh, M., Hussaini, S., Vidya, H., Srinivas Garlapati., Rabindra, R.J. and Singh, S.P. (2005) Complete sequence of 16s rRNA gene of Indian isolate of Photorhabdus luminescens NCBI Accession numbers: AY594267.2, DQ026510, DQ026511, DQ026512, AY660026

My contributions to the work involved analysis of the DNA sequence, and submission of the sequence to the Genbank.

3. Srinivas Garlapati, (2000) Trypanosoma evansi RAPD fragment. Thesis (2000) Indian Veterinary Research Institute(Deemed University) NCBI Accession numbers: AJ278680.1; AJ278679.1

Book

1. Srinivas Garlapati (2025). Healthcare  Administration & Management - A Canadian Context" Published by Springer Nature, Switzerland 

2.  Singh Rajkumar and Srinivas Garlapati(2006) Applications of Bioinformatics in Animal Biotechnology in “A text book of Animal Biotechnology”. Edited by Yadav, MP, Singh RK & Srivastava, AK. Published by IBH Oxford, New Delhi 2006.

Theses

1. Development of Sheeppox virus vectored vaccine for Foot-and-Mouth Disease

· The vectored vaccine provided dual protection against both Sheeppox and FMD.

· The vectored vaccine was found to be efficacious in sheep when used in a heterologous prime boost regimen with DNA and protein sub-unit vaccines.

2. RAPD-PCR based Diagnosis of Trypanosoma evansi.

· A cloned RAPD DNA was cloned and sequenced.

· A PCR assay was developed based on the novel sequence and used to detect carrier status of Trypanosomiasis in domestic animals.

Conferences/Symposiums/Workshops

1. Sylvia van Drunen Littel-van den Hurk, Srinivas Garlapati, Laura Latimer, Volker Gerdts, and Lorne Babiuk. Formulation of respiratory syncytial virus vaccine with a novel adjuvant platform induces protective immune responses in cotton rats and mice. The 7th International Respiratory Syncytial Virus Symposium. Rotterdam, the Netherlands, Dec. 2-5, 2010

2. Srinivas Garlapati, Nelson F Eng, Mutwiri George, Lorne Babiuk, Volker Gerdts Immunization with novel particle-based vaccine formulations confers protection against pertussis. Presented at Ninth International Bordetella Symposium,Baltimore, MD, USA Sep 30 – Oct 2, 2010

3. Srinivas Garlapati, Nelson F. Eng, Mutwiri George, Lorne Babiuk, Volker Gerdts PCEP Polyphospazene Microparticle Delivery of Novel Vaccine Formulations against Pertussis. The Third International Conference on Modern Vaccines Adjuvants & Delivery Systems. Vienna, Austria, Oct 28-30 2009

4. Srinivas Garlapati,Nelson F. Eng, Mutwiri George, Lorne Babiuk, Volker Gerdts. Microparticle formulation consisting of CpG ODN, Innate defense regulator peptide and PCEP induced potent Th1 responses in mice. A symposium of the 23rd Annual Spring Meeting of the Canadian Society of Immunology, Niagara Falls. Ontario, Apr 23-26, 2010